Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Vor Biopharma Inc. (NYSE:VOR) has received a consensus recommendation of "Moderate Buy" from nine research firms, with four hold ratings and five buy ratings.
• The average 1-year price target among analysts is $6.07, reflecting optimism about the company’s growth.
• Institutional investors hold 97.29% of Vor Biopharma's stock, indicating significant confidence from large stakeholders.

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $6.0667.

Several equities research analysts have recently weighed in on the stock. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Citizens Jmp lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $3.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Finally, JMP Securities restated a "market perform" rating and set a $6.00 target price on shares of Vor Biopharma in a research report on Friday, May 9th.

Vor Biopharma Trading Down 1.8%

NYSE:VOR traded down $0.04 during trading hours on Friday, hitting $1.97. 2,284,551 shares of the company traded hands, compared to its average volume of 7,799,451. The stock has a market capitalization of $248.93 million, a price-to-earnings ratio of -1.18 and a beta of 2.06. The firm has a 50-day moving average of $1.89 and a 200 day moving average of $1.08. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $3.29.

Insider Transactions at Vor Biopharma

In related news, major shareholder Reprogrammed Interchange Llc sold 284,190 shares of the stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $2.08, for a total transaction of $591,115.20. Following the completion of the sale, the insider directly owned 38,302,565 shares of the company's stock, valued at approximately $79,669,335.20. This represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.45% of the company's stock.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP grew its stake in shares of Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after acquiring an additional 25,930 shares in the last quarter. Money Concepts Capital Corp raised its position in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares during the period. XTX Topco Ltd bought a new position in shares of Vor Biopharma in the second quarter valued at about $66,000. Northern Trust Corp raised its position in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after purchasing an additional 44,252 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares during the period. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.